01 Industry overview
The data integrity pharmaceutical industry at a glance
Data integrity has become a measurable pharmaceutical compliance market: quality-management software reached $2.1B in 2025, while FDA-linked data-integrity findings continued across manufacturing, laboratories and clinical research.
- $2.1B[66]
- Global QMS software market, 2025
- 13.8%[66]
- QMS software CAGR, 2026–2033
- 40.0%[66]
- North America share, 2025
- 95[67]
- FDA-linked DI findings, 2025
- Market size
- The closest quantified proxy for the data-integrity pharmaceutical industry is pharmaceutical quality-management software, which generated $2.1 billion globally in 2025. The data-management application itself represented 17.5% of 2025 revenue, equivalent to approximately $367 million on the reported market base.[66]
- Forecast & CAGR
- The global pharmaceutical quality-management software market is projected to reach $5.8 billion by 2033 from $2.1 billion in 2025, representing a 13.8% CAGR for 2026–2033. The U.S. market is forecast to grow at a 14.1% CAGR from 2026 to 2033.[66]
- Market share & regions
- North America held 40.0% of global pharmaceutical quality-management software revenue in 2025. The United States accounted for 35.9% of the global market, while Asia Pacific was identified as the fastest-growing region through 2033.[66]
- Segmentation
- By application, data management led the U.S. market with a 19.93% revenue share in 2025; the broader global data-management segment held 17.5%. By deployment, cloud and web-based systems accounted for 77.2% of global revenue in 2025, compared with on-premise systems.[66]
- Trends, drivers & challenges
- FDA enforcement data compiled by GMPNews shows data-integrity, records and documentation issues in 95 warning letters in 2025, up from 78 in 2024. FDA’s FY2025 Office of Compliance report recorded 314 drug warning letters overall, with 32% involving drug-manufacturing CGMP or adulteration violations, highlighting compliance risk as a major adoption driver.[67][56]
- Regulation
- FDA’s data-integrity guidance applies to CGMP requirements for drugs under 21 CFR parts 210, 211 and 212 and expects data to be reliable and accurate. FDA also references the April 2024 guidance for in-vivo bioavailability and bioequivalence studies and the September 2025 ICH E6(R3) Good Clinical Practice guidance in its data-integrity notifications.[56]
- Latest news
- On October 14, 2026, FDA issued a warning letter to Rohto Pharmaceutical describing falsified environmental-monitoring, process-monitoring and cleaning records, stating that the breaches undermined assurance of sterility for U.S.-distributed drug products. In March 2025, FDA separately rejected certain Raptim Research bioequivalence data after identifying significant data-integrity and study-conduct concerns.[56]
02 Ranking
Top 10 Companies in the Data Integrity Pharmaceutical Industry
The leading companies in the data integrity pharmaceutical industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 11, 2026 · Next review December 11, 2026
Waters leads Gitnux's 2026 data integrity pharmaceutical ranking with an Overall score of 9.0, with supplies analytical technologies and informatics for regulated pharmaceutical testing. Agilent Technologies is the runner-up at 8.8, driven by 6.7% revenue growth and a 21.3% operating margin.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in analytical instruments & data systems
Waters
US
Ranked #1 · 9.0 · Analytical instruments & data systems
Why we picked it: Waters targets regulated pharmaceutical testing with analytical informatics and services.
Leader in regulated QMS
Veeva Systems
US
Ranked #3 · 8.8 · Regulated QMS
Why we picked it: Veeva provides regulated cloud applications that support quality work in life sciences.
Leader in pharma laboratory informatics
Thermo Fisher Scientific
US
Ranked #4 · 8.7 · Pharma laboratory informatics
Why we picked it: Thermo Fisher supplies LIMS to manage regulated pharmaceutical laboratory data workflows.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Company snapshot |
|---|---|---|---|---|
| 1 | Waters Analytical instruments & data systems · US | 9.0 | 8.9 | |
Company snapshot · Waters · Data as of November 11, 2026 Waters supplies analytical technologies, informatics and services for regulated pharmaceutical testing.[68]
| ||||
| 2 | Agilent Technologies Analytical instruments & data systems · US | 8.8 | 8.6 | |
Company snapshot · Agilent Technologies · Data as of November 11, 2026 Agilent provides laboratory instruments, software and workflow solutions used in pharmaceutical testing.[69]
| ||||
| 3 | Veeva Systems Regulated QMS · US | 8.8 | 8.9 | |
Company snapshot · Veeva Systems · Data as of November 11, 2026 Veeva provides Vault Quality Cloud and other regulated life-sciences applications.[70]
| ||||
| 4 | Thermo Fisher Scientific Pharma laboratory informatics · US | 8.7 | 9.6 | |
Company snapshot · Thermo Fisher Scientific · Data as of November 11, 2026 Thermo Fisher offers SampleManager LIMS for regulated pharmaceutical laboratory data workflows.[71]
| ||||
| 5 | Honeywell Technologies Regulated QMS · US | 8.6 | 9.9 | |
Company snapshot · Honeywell Technologies · Data as of November 11, 2026 TrackWise supports more than 825,000 users across pharmaceutical, biotech and medical-device companies.[72]
| ||||
| 6 | Dassault Systèmes BIOVIA pharma laboratory, quality and manufacturing data · FR | 8.6 | 8.0 | |
Company snapshot · Dassault Systèmes · Data as of November 11, 2026 BIOVIA provides audit trails, validation workflows and traceability for regulated life-sciences data.[73]
| ||||
| 7 | Siemens Pharma MES and electronic batch records · DE | 8.5 | 8.0 | |
Company snapshot · Siemens · Data as of November 11, 2026 Opcenter Execution Pharma records and reviews compliant pharmaceutical production data.[74]
| ||||
| 8 | MasterControl Pharma QMS, manufacturing and electronic records · US | 8.4 | 8.0 | |
Company snapshot · MasterControl · Data as of November 11, 2026 MasterControl provides cloud quality and manufacturing software for life-sciences companies.[75]
| ||||
| 9 | Körber Pharma MES and electronic batch records · DE | 8.1 | 8.0 | |
Company snapshot · Körber · Data as of November 11, 2026 Körber PAS-X supports pharmaceutical electronic batch recording and data integrity.[76]
| ||||
| 10 | ComplianceQuest Pharma QMS, risk and compliance software · US | 7.9 | 7.0 | |
Company snapshot · ComplianceQuest · Data as of November 11, 2026 ComplianceQuest supports pharmaceutical QMS workflows and GxP data integrity requirements.[77]
| ||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 11, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 11). Top 10 companies in the data integrity pharmaceutical industry. In Data Integrity Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/data-integrity-pharmaceutical-industry-statistics/#top-companies
FDA notifications regarding pharmaceutical data-integrity concerns
FDA notifications regarding pharmaceutical data-integrity concerns grew from 1 in 2011 to 1 in 2025.
03 Trends & forecasts
Top 10 Data Integrity Pharmaceutical Industry Trends & Forecasts 2027
What is changing in the data integrity pharmaceutical industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01QMS spending accelerates through 2027
High confidenceGlobal pharmaceutical quality-management software revenue reached $2.1 billion in 2025 and is projected to grow at a 13.8% CAGR from 2026 to 2033. The market is estimated at $2.3 billion in 2026, indicating continued expansion into 2027.[66]
Forecast 2027: Revenue should approach approximately $2.6 billion in 2027 if the reported growth path holds. Demand will remain strongest where quality systems can combine compliance, audit readiness and operational data.
02Data-management software gains share
High confidenceData management generated $367.0 million globally in 2025, representing 17.5% of pharmaceutical QMS revenue, and is forecast to reach $1.04 billion by 2033 at a 14.1% CAGR.[66]
Forecast 2027: The data-management segment should exceed $400 million in 2027 and remain one of the fastest-growing QMS applications as companies consolidate laboratory, manufacturing and clinical records.
03Cloud deployment continues dominating
High confidenceCloud and web-based pharmaceutical QMS accounted for 77.2% of global revenue in 2025 and was identified as the fastest-growing deployment mode in the forecast period.[66]
Forecast 2027: Cloud-based systems should increase their share further in 2027, although hybrid architectures will remain important for sites with legacy equipment, local validation requirements or data-residency constraints.
04North America retains market leadership
High confidenceNorth America held 40.0% of global pharmaceutical QMS revenue in 2025. The United States alone generated $750.3 million, or 35.9% of global revenue.[66]
Forecast 2027: North America should remain the largest regional market in 2027, supported by mature FDA compliance programs and high enterprise software adoption, while Asia Pacific grows faster from a smaller base.
05Asia Pacific expands fastest
Medium confidenceAsia Pacific is identified as the fastest-growing regional market for pharmaceutical QMS through 2033. The data-management outlook also identifies India as the country expected to register the highest CAGR from 2026 to 2033.[66]
Forecast 2027: In 2027, investment should rise particularly among Indian and other Asian manufacturers, laboratories and contract research organizations serving regulated export markets.
06Regulatory pressure sustains demand
High confidenceFDA issued 314 drug warning letters in fiscal 2025, with 32% involving drug-manufacturing CGMP or adulteration violations. FDA guidance states that drug firms must ensure data are reliable and accurate under CGMP requirements.[56]
Forecast 2027: Regulatory exposure should remain the principal demand driver in 2027, shifting purchasing toward systems that provide traceability, electronic records, audit trails and documented remediation.
07Data-integrity findings remain elevated
High confidenceFDA-linked data-integrity, records and documentation issues appeared in 95 warning letters in 2025, up from 78 in 2024, according to the industry compilation described in the overview. FDA separately rejected certain Raptim Research study data in March 2025 after identifying integrity and study-conduct concerns.[56]
Forecast 2027: The elevated findings rate should keep data-integrity remediation and independent data reviews active through 2027, especially in laboratories, bioequivalence studies and manufacturing records.
08Clinical-data controls broaden globally
High confidenceICH E6(R3) became effective on July 23, 2025, introducing risk-based principles for modern trial designs, data sources and technologies. The guideline requires documented processes that preserve data integrity across the full data life cycle.[78][79]
Forecast 2027: By 2027, sponsors and CROs should spend more on end-to-end clinical-data governance, including source-data oversight, metadata retention, transfer reconciliation and risk-based computerized-system controls.
09Outsourced-study oversight intensifies
High confidenceFDA data-integrity notifications list unacceptable clinical or bioanalytical studies from Raptim Research in 2025 and Synapse Labs in 2024, following earlier actions involving other contract laboratories. WHO guidance states that contract givers remain responsible for the integrity of data supplied by contract acceptors.[56][80]
Forecast 2027: Pharmaceutical companies should intensify CRO qualification, quality agreements, remote monitoring and raw-data access in 2027, increasing demand for supplier-quality and oversight modules.
10AI validation becomes a quality requirement
Medium confidenceFDA’s January 2025 draft guidance proposes a risk-based credibility framework for AI models used to support drug-product regulatory decisions. FDA and EMA principles published in January 2026 emphasize data governance, documentation, performance assessment and life-cycle management.[56]
Forecast 2027: In 2027, AI-enabled quality and laboratory tools should move from experimentation toward controlled deployment, with validation packages, model-change records and human review becoming standard buying criteria.
04 Statistics
Technology & Innovation
In 2025–2026, AI and automation signals show up alongside documentation maturity. Cloud and AI usage sit next to expressed concern around model and data integrity.
AI in the data integrity pharmaceutical industry
- 31% of pharmaceutical and biotechnology organizations had deployed AI for multilingual translation and local customization in regulatory work in 2025.[1]
- 52% of pharmaceutical and biotechnology executives said their organizations use a hybrid mix of internal development, partnerships and acquisitions to build AI capabilities in R&D in 2025.[1]
- 82% of pharmaceutical and biotechnology executives said AI will fundamentally transform biopharma R&D within five years in 2025.[1]
- 38% of pharmaceutical and biotechnology organizations were exploring AI-agent applications in R&D in 2025.[1]
- 63% of pharmaceutical and biotechnology executives said most new molecular entities will originate from AI-driven platforms within the next decade in 2025.[1]
- 65% of healthcare, biotechnology and pharmaceutical respondents identified model and data integrity as an AI-related concern in 2025.[2]
Automation in the data integrity pharmaceutical industry
- 18% of responding pharmaceutical companies could gather CPV data for a product in less than one hour in 2022.[3]
- 19% of pharmaceutical businesses reported fully digital documentation in the 2025 pharmaceutical manufacturing survey.[4]
- 46% of responding pharmaceutical companies had medium-to-advanced digital data management with integrated electronic data solutions in 2022.[3]
- 25% of pharmaceutical companies had estimated the cost of digitizing or automating ongoing verification, with projected costs of €300,000–€1 million, in 2022.[3]
- 74% of pharmaceutical businesses said digitization efforts were a major part of ongoing business activities in 2025.[4]
- 3% of pharmaceutical businesses reported having no digital documentation in 2025.[4]
Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)
- 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[5]
- 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[5]
- 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[3]
- 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[6]
- 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[3]
Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)
- 55% of biopharma AI adopters reported using AI in process development in 2024.[7]
- 70% of global biopharma respondents had adopted an R&D data platform in 2023.[8]
- 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[9]
- 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[8]
- 63% of global biopharma respondents had adopted robotics and automation in 2023.[8]
Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)
- 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[10]
- 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[11]
- 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[7]
- 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[8]
- 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[7]
Big Data in the pharmaceuticals and biotech sector (sector benchmark)
05 Statistics
Data & Analytics
Data structure and governance remain constraints for scaling AI. In 2025, 81% of commercial biopharma leaders cited data quality as a top issue for the next 12 months.
Business intelligence in the data integrity pharmaceutical industry
- 23% of small biopharma companies and 17% of large biopharma companies had adopted cloud-based scientific software or SaaS, according to a 2024 survey.[9]
- 68% of pharmaceutical companies planned to use advanced analytics in 2024, according to industry research cited by Axiobench.[13]
- 33% of biopharma survey respondents reported using data lakes in day-to-day operations in 2021, according to industry research cited by Axiobench.[13]
- 37% of respondents at small biopharma companies reported that more than 60% of their R&D laboratory instruments had automated data capture, in a 2024 survey.[9]
Data analytics in the data integrity pharmaceutical industry
- 18% of surveyed biopharma executives were digitally or technologically oriented, according to a 2025 survey of 500 pharmaceutical and biotechnology executives.[1]
- 17% of surveyed biopharma executives worked in information technology, according to a 2025 survey of 500 pharmaceutical and biotechnology executives.[1]
- 15% of surveyed biopharma executives worked in innovation, according to a 2025 survey of 500 pharmaceutical and biotechnology executives.[1]
- 36% of surveyed biopharma executives were clinically oriented, according to a 2025 survey of 500 pharmaceutical and biotechnology executives.[1]
- 8% of surveyed biopharma executives worked in digital health or biomarkers, according to a 2025 survey of 500 pharmaceutical and biotechnology executives.[1]
- 46% of surveyed biopharma executives were both clinically and digitally or technologically oriented, according to a 2025 survey of 500 pharmaceutical and biotechnology executives.[1]
Data Quality in the pharmaceuticals and biotech sector (sector benchmark)
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[14]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[14]
- Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[1]
- Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[14]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[14]
Data Governance in the pharmaceuticals and biotech sector (sector benchmark)
- Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[15]
- Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[15]
- Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[16]
- Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[1]
- Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[15]
KPIs in the data integrity pharmaceutical industry
- 45% of surveyed pharmaceutical companies tracked service level as a KPI, according to a 2026 benchmarking survey of 31 companies.[17]
- 55% of surveyed pharmaceutical companies tracked escalation rate as a KPI, according to a 2026 benchmarking survey of 31 companies.[17]
- 55% of surveyed pharmaceutical companies tracked topics or question categories as a KPI, according to a 2026 benchmarking survey of 31 companies.[17]
- 65% of surveyed pharmaceutical companies tracked the number of documents created or updated as a KPI, according to a 2026 benchmarking survey of 31 companies.[17]
- 61% of surveyed pharmaceutical companies differentiated between metrics and KPIs, according to a 2026 benchmarking survey of 31 companies.[17]
- 77% of surveyed pharmaceutical companies tracked response turnaround time as a KPI, according to a 2026 benchmarking survey of 31 companies.[17]
06 Statistics
Strategy & Growth
Forecasts tie growth to quality-control and compliance software spend. QMS software is projected to rise to $5.8B by 2033 from $2.1B in 2025.
Growth in the data integrity pharmaceutical industry
- The pharmaceutical data-management software market was valued at $4.23 billion in 2024 and projected to reach $10.5 billion by 2035.[18]
- The small-molecule-drug segment was expected to hold 54.3% of the pharmaceutical quality-control and compliance market in 2026.[19]
- The software segment of the pharmaceutical quality-control and compliance market was projected to grow at a 12.03% CAGR.[19]
- The global pharmaceutical quality-control and compliance market was valued at $10.79 billion in 2025.[19]
- The global pharmaceutical quality-control and compliance market was projected to reach $22.82 billion by 2034.[19]
- The global data integrity and compliance systems market was projected to expand at a 15.80% CAGR from 2024 to 2033.[20]
07 Statistics
People & Workforce
Workforce constraints focus on skills for data and AI use. In 2025, 96% of data leaders said staff need more AI or data-literacy training to use AI responsibly.
Hiring in the data integrity pharmaceutical industry
- 2.9 million life-sciences job postings were analyzed in the 2025 U.S. workforce trends report.[21]
- 58% of R&D professionals changing roles in 2024 moved to another pharmaceutical company.[22]
- 16% was the increase in life-sciences job postings for data-science roles between 2019 and 2024.[10]
- 0.3% was the U.S. life-sciences employment contraction reported for 2024 after several years of rapid post-pandemic hiring.[23]
- 50% of employed life-sciences professionals said they planned to actively seek a new role in 2024.[24]
Employee retention in the data integrity pharmaceutical industry
- 58% of R&D professionals who changed roles in 2024 remained within pharmaceutical companies, indicating continued sector retention.[22]
- 11% of R&D professionals changing roles in 2024 moved to social-sector organizations.[22]
- 7% of R&D professionals changing roles in 2024 moved into medical-products positions outside pharmaceutical companies.[22]
Remote Work in the pharmaceuticals and biotech sector (sector benchmark)
- Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[25]
- Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[26]
- Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[27]
- Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[25]
Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)
- Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[28]
- Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[29]
- Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[26]
- Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[30]
Upskilling in the data integrity pharmaceutical industry
- 71% of pharmaceutical companies reported having personnel trained in statistics or data science for continued process verification in 2022.[3]
- 96% of data leaders said staff need more AI or data-literacy training to use AI responsibly in 2025.[31]
- 83% of surveyed biopharmaceutical supply-chain leaders said a significant portion of their workforce needs upskilling or reskilling for digital transformation in 2024.[10]
Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)
- At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[32]
- Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[33]
- Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[33]
- Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[33]
DEI in the data integrity pharmaceutical industry
- 97% of surveyed life-sciences companies said advancing DEI as a strategic priority had remained unchanged or increased in the 2023 industry hiring survey.[34]
- 33.6% of surveyed life-sciences companies said DEI had increased as a strategic priority during the prior year in 2023.[34]
- 19.7% of surveyed life-sciences companies reported holding DEI-related forums or events in 2023.[34]
- 11.3% of surveyed life-sciences companies had established a chief diversity officer or similar leadership position in 2023.[34]
- 46.3% of surveyed life-sciences companies reported building an inclusive culture as a DEI approach in 2023.[34]
Change Management in the pharmaceuticals and biotech sector (sector benchmark)
- Among pharmaceutical and biotechnology executives surveyed, 26% expected to conduct a significant acquisition within the following 12 months in 2023.[35]
- Across 612 pharmaceutical-company respondents, clinical-trial innovations took an average of 69 months from planning to portfolio-wide implementation, excluding decentralized-trial adoption during COVID-19.[36]
08 Statistics
Customer & Sales
Commercial adoption hinges on trustworthy and accurate information. In 2019, 78% of surveyed patients rated trustworthiness as important.
Customer experience in the data integrity pharmaceutical industry
- 78% of surveyed patients in Europe and the United States rated trustworthiness as an important factor when pharmaceutical companies share information or provide a service in 2019.[37]
- 46% of North American life-sciences professionals said their organizations planned to invest in new sources of customer-reference data within the following year in 2020.[14]
- 88% of surveyed patients in Europe and the United States rated accuracy as an important factor when pharmaceutical companies share information or provide a service in 2019.[37]
- 83% of North American life-sciences professionals said customer-reference-data quality has a moderate or major impact on field-representative satisfaction with CRM in 2020.[14]
- 35% of North American life-sciences professionals said their organizations planned to outsource or invest more in data-stewardship services within the following year in 2020.[14]
Customer acquisition in the data integrity pharmaceutical industry
- 81% of North American life-sciences professionals considered customer-reference data very important or essential to field-force effectiveness in 2020.[14]
- 96% of North American life-sciences professionals considered customer-reference data important, very important or essential for account-based selling in 2020.[14]
- 88% of North American pharmaceutical field representatives used digital channels to reach and engage healthcare professionals in 2020.[14]
- 92% of North American life-sciences professionals considered customer-reference data important, very important or essential for product launches in 2020.[14]
- 93% of North American life-sciences professionals considered customer-reference data important, very important or essential for territory planning in 2020.[14]
09 Statistics
Marketing & Brand
Regulatory-compliance scrutiny affects AI usage in promotional work. In 2025, 65% of U.S. marketing professionals said they distrusted AI for regulatory-compliance submissions.
Marketing in the data integrity pharmaceutical industry
Digital marketing in the data integrity pharmaceutical industry
- 48% was the pharmaceutical industry’s digital-marketing skills score for email marketing in the 2023 benchmark.[39]
- 26% was the pharmaceutical industry’s digital-marketing skills score for online advertising in the 2023 benchmark.[39]
- 38% was the pharmaceutical industry’s digital-marketing skills score for usability in the 2023 benchmark.[39]
- 37% was the pharmaceutical industry’s digital-marketing skills score for digital strategy in the 2023 benchmark.[39]
- 33% was the pharmaceutical industry’s digital-marketing skills score for mobile marketing in the 2023 benchmark.[39]
Branding in the data integrity pharmaceutical industry
- 60% of surveyed brand-side pharmaceutical marketers worked for companies with more than $10 billion in annual revenue in the 2026 Pharma Marketing Pulse study.[40]
- 30% of respondents in the 2026 Pharma Marketing Pulse study represented neurology as a primary therapeutic area.[40]
- 58% of surveyed pharmaceutical marketers in the 2026 Pharma Marketing Pulse study worked for pharma brands.[40]
- 47% of respondents in the 2026 Pharma Marketing Pulse study represented oncology as a primary therapeutic area.[40]
- 42% of surveyed pharmaceutical marketers in the 2026 Pharma Marketing Pulse study worked for agency organizations.[40]
Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)
- 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[43]
- 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[44]
- 50% of healthcare and pharmaceutical marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, globally.[44]
- 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[43]
- 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[45]
10 Statistics
Operations & Execution
FDA enforcement data keeps validation and documentation in focus. In 2025, data-integrity, records and documentation issues appeared in 95 warning letters.
Process optimization in the data integrity pharmaceutical industry
- 26% of FDA CGMP warning letters to pharmaceutical manufacturers in 2010–2020 cited validation deficiencies, including process, analytical-method, material or equipment validation issues.[46]
- 25–30% of FDA pharmaceutical CGMP warning letters each year from 2010 to 2020 mentioned validation-related violations.[46]
- The FDA issued 3,777 warning letters to pharmaceutical and medical-device manufacturers from 2010 to 2020, after issuing 6,830 letters overall.[46]
- 25–31% of FDA pharmaceutical CGMP warning letters across regions from 2010 to 2020 involved validation deficiencies.[46]
Operational efficiency in the data integrity pharmaceutical industry
- The average number of data-integrity violations per cited pharmaceutical company increased in 2023, according to an analysis of FDA warning letters.[47]
- Data-integrity violations involving endurance, availability and completeness increased year over year after 2020 in the analyzed FDA pharmaceutical warning-letter dataset.[47]
- 1,766 FDA warning letters issued from 2016 to 2023 were analyzed to classify pharmaceutical data-integrity violations under ALCOA and ALCOA+ principles.[47]
Quality management in the data integrity pharmaceutical industry
- Approximately 12–15% of FDA pharmaceutical CGMP warning letters from 2010 to 2020 cited quality-control issues.[46]
- 88.3% of FDA CGMP warning letters issued through May 2024 concerned over-the-counter drugs, compared with 8.3% for APIs and 3.3% for prescription drugs.[48]
- 60 FDA CGMP warning letters had been issued by CDER by May 2024, including 21 to US firms, 7 to Chinese firms and 7 to Indian firms.[48]
- About 20–24% of FDA pharmaceutical CGMP warning letters across regions from 2010 to 2020 cited documentation deficiencies, with Europe reporting the highest level.[46]
- 15% of FDA pharmaceutical CGMP warning letters from 2010 to 2020 cited quality-control deficiencies.[46]
Supply chain in the data integrity pharmaceutical industry
- FDA inspectors identified supply-chain globalization and contract manufacturing among recurring control issues discussed for pharmaceutical manufacturers in 2024.[48]
- More than 65% of FDA CGMP warning letters issued to pharmaceutical and medical-device manufacturers from 2010 to 2020 went to companies in Asia, primarily India and China.[46]
Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)
- 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[6]
- 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[6]
- 67% of global biotech and pharma companies outsourced pharmacovigilance operations in 2024, according to an IQVIA industry report.[49]
- 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[49]
- 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[50]
11 Statistics
Product & Service
End users describe compliance difficulty tied to testing and data integrity. In 2025, 13% identified cybersecurity and data integrity as a difficult compliance requirement.
Product development in the data integrity pharmaceutical industry
- 44 pharmacometric-services colleagues from 32 companies were surveyed about data-quality impacts on model-informed drug development deliverables in 2025.[51]
- 50% of surveyed pharmacometric CRO respondents identified missing definitions or specifications as the primary reason sponsor data were difficult to use, in 2025.[51]
- 9% of 500 surveyed pharmaceutical and biotechnology executives worked in data and analytics, according to a 2025 global biopharma survey.[1]
- 8% of 500 surveyed pharmaceutical and biotechnology executives worked in manufacturing process development, according to a 2025 global biopharma survey.[1]
- 3–24 hours was the reported time required for CROs to clean one sponsor dataset, according to a 2025 pharmacometric-services survey.[51]
Product lifecycle in the data integrity pharmaceutical industry
- 19% of surveyed pharmaceutical businesses reported fully digital documentation, according to research cited in PMMI’s 2025 manufacturing report.[4]
- 49% of surveyed pharmaceutical-manufacturing end users identified product testing and quality verification as a difficult compliance requirement, in 2025.[4]
- 32% of surveyed pharmaceutical businesses reported some digital documentation but primarily manual documentation, according to PMMI’s 2025 report.[4]
- 20% of surveyed pharmaceutical-manufacturing end users identified labeling information and accuracy as a difficult compliance requirement, in 2025.[4]
- 29% of surveyed pharmaceutical-manufacturing end users identified material and ingredient testing or verification as a difficult compliance requirement, in 2025.[4]
After-sales in the data integrity pharmaceutical industry
- 3% of surveyed pharmaceutical businesses reported having no digital documentation, according to research cited in PMMI’s 2025 manufacturing report.[4]
- 56% of surveyed pharmaceutical end users planned to purchase pharmaceutical packaging or processing machinery within the following year, according to research conducted in late 2025.[52]
- 13% of surveyed pharmaceutical-manufacturing end users identified cybersecurity and data integrity as a difficult compliance requirement, in 2025.[4]
- 42% of surveyed pharmaceutical end users expected pre-filled syringes or injectors to achieve the greatest volume growth over the following three years, according to research conducted in late 2025.[52]
Value proposition in the data integrity pharmaceutical industry
- 46% of surveyed pharmaceutical businesses reported an approximately even mix of digital and manual documentation, according to PMMI’s 2025 manufacturing research.[4]
- 55% of surveyed pharmaceutical manufacturers had established a data center of excellence, according to a 2023 industry survey reported by Pharma Manufacturing.[12]
- 74% of surveyed pharmaceutical businesses said digitization efforts were a major part of their ongoing business activities, according to PMMI’s 2025 manufacturing research.[4]
- 43% of IT respondents at large biopharma companies supported more than 20 scientific software applications, according to a 2024 survey.[9]
12 Statistics
Sustainability & Ethics
Integrating operational and sustainability information adds another data-control burden. In 2025, 58% of European organizations reported difficulty integrating data across multiple systems.
Sustainability in the data integrity pharmaceutical industry
- 48% of European pharmaceutical companies conduct packaging sustainability initiatives, according to a 2025 survey of regulatory and quality leaders.[53]
- 56% of European pharmaceutical companies prioritize energy efficiency in good manufacturing practice operations, according to a 2025 industry survey.[53]
- 58% of European pharmaceutical organizations reported difficulty integrating data across multiple systems in a 2025 survey, affecting the reliability of operational and sustainability information.[53]
- 46% of European pharmaceutical companies increased technology investments during the three years before a 2025 survey, linking digital transformation with quality and sustainability management.[53]
- 84% of European pharmaceutical organizations embed environmental metrics into quality management systems, according to a 2025 survey of 100 senior regulatory and quality leaders in Europe and the UK.[53]
ESG in the data integrity pharmaceutical industry
- 33% of pharmaceutical-industry leaders prioritize quality-culture transformation over purely technical controls, according to a 2025 European survey.[53]
- 27% of North America’s top 100 pharmaceutical companies disclosed independent verification of sustainability data in SGS research published in 2025.[54]
- 50% of European pharmaceutical companies target carbon-footprint reduction, according to a 2025 survey of 100 senior regulatory and quality leaders.[53]
- 53% of European pharmaceutical companies had implemented advanced risk-based quality systems in 2025, according to an NSF survey of industry leaders.[53]
Ethics in the data integrity pharmaceutical industry
- 33% of Indian pharmaceutical companies surveyed by EY reported sharing employee login IDs and passwords for laboratory systems, according to 2015 survey results.[55]
- 25% of Indian pharmaceutical employees surveyed were unaware of U.S. FDA 21 CFR Part 11 requirements, according to an EY data-integrity study reported in 2015.[55]
- 57% of Indian pharmaceutical employees surveyed had seen manufacturing personnel experience work pressure to meet production KPIs, according to EY findings published in 2015.[55]
- 18% of Indian pharmaceutical respondents reported that their quality-assurance teams were not adequately staffed to review manufacturing and testing independently, according to a 2015 EY survey.[55]
13 Statistics
Risk, Compliance & Legal
Regulatory outcomes and cybersecurity risk remain coupled to data-integrity concerns. In 2025, 314 human-drug warning letters were issued by the U.S. FDA.
Compliance in the data integrity pharmaceutical industry
- 314 human-drug warning letters were issued by the U.S. FDA in 2025, covering manufacturing, clinical research, misbranding and other pharmaceutical compliance violations.[56]
- 42 Preliminary Notices of Noncompliance and 2 Notices of Noncompliance were issued for ClinicalTrials.gov registration and reporting failures in 2025.[56]
- 13% of pharmaceutical manufacturing end users identified cybersecurity and data integrity as regulatory challenges in a 2025 PMMI survey.[4]
- 590 inspections and remote regulatory assessments of sponsors, contract research organizations, investigators and institutional review boards were conducted or reviewed by the U.S. FDA in 2025.[56]
- Nearly 90% of parties receiving U.S. FDA ClinicalTrials.gov noncompliance notices in 2025 subsequently posted the required clinical-trial information.[56]
Risk Management in the pharmaceuticals and biotech sector (sector benchmark)
- 81% of middle-market life sciences companies said risk management was a top priority, rising to 90% among the fastest-growing organizations.[57]
- 85% of global life science firms had a formal business continuity process covering the whole business in 2024.[58]
- 52% of middle-market life sciences companies reported having a business continuity plan in place.[57]
- 90% of clinical trials managed by surveyed CROs included at least one risk-based monitoring or risk-based quality-management component in 2025.[59]
- 44% of global life science firms reported no standardized or consistently effective intellectual-property risk-management process in 2024.[58]
Cybersecurity in the pharmaceuticals and biotech sector (sector benchmark)
- 40% of surveyed pharmaceutical businesses experienced outages affecting productivity, safety, compliance, revenue, or brand image.[60]
- 27% of healthcare, biotechnology, and pharmaceutical respondents had little or no confidence in identifying where their data was stored in 2025.[2]
- 52% of surveyed middle-market life sciences companies reported experiencing a cybersecurity breach.[57]
- 98% of surveyed pharmaceutical firms experienced at least one cybersecurity intrusion in the 12 months covered by Fortinet’s 2021 survey.[60]
- 28% of surveyed pharmaceutical businesses lost business-critical data or intellectual property because of cybersecurity incidents.[60]
Data Privacy in the pharmaceuticals and biotech sector (sector benchmark)
- 84% of surveyed pharmaceuticals and life sciences organizations said measuring and managing sensitive-content compliance required some to significant improvement in 2024.[61]
- 66% of pharma, biotech, and medical-device respondents said patient privacy presented a challenge when complying with journal data-sharing policies in 2024.[62]
- Stricter privacy regulation was associated with an approximately 39% reduction in R&D spending by global pharmaceutical and biotechnology firms four years after implementation.[63]
- 61% of surveyed pharmaceuticals and life sciences organizations identified GDPR as a top-two privacy and compliance focus in 2024.[61]
- 39% of surveyed pharmaceuticals and life sciences organizations said they tagged and classified around three-quarters of their unstructured data in 2024.[61]
Crisis Management in the pharmaceuticals and biotech sector (sector benchmark)
- 50% of surveyed global life science firms identified logistics and warehousing shortages as a major supply-chain risk for the following two years.[58]
- 40% of surveyed pharmaceutical firms maintained inventory buffers of one to three months to protect against supply-chain disruption.[64]
- 61% of surveyed global life science firms identified panic buying and stockpiling as a major supply-chain risk for the following two years.[58]
- 52% of surveyed global life science firms identified contract-manufacturing issues as a major supply-chain risk for the following two years.[58]
- 48% of surveyed global life science firms identified natural disasters as a major supply-chain risk for the following two years.[58]
Governance in the data integrity pharmaceutical industry
- 37% of European pharmaceutical leaders identified compliance with Annex 1 as their top challenge in 2025, according to an NSF industry survey.[53]
- 32% of European pharmaceutical leaders identified raw-material sourcing as their most pressing challenge in 2025, according to an NSF survey focused on quality, risk and data integration.[53]
- 23% of European pharmaceutical companies operated with only basic compliance-level quality systems in 2025, according to an NSF survey of 100 senior regulatory and quality leaders.[53]
- 42% of pharmaceutical manufacturing end users reported digitizing documentation and regulatory reporting to meet requirements in a 2025 PMMI survey.[4]
14 Statistics
Globalization & Expansion
Geography shifts show up in forecasted revenue for quality and compliance spend. Asia-Pacific quality-control and compliance revenue is projected to reach $2.76B in 2026.
Globalization in the data integrity pharmaceutical industry
- Asia-Pacific pharmaceutical quality-control and compliance revenue was projected to reach $2.76 billion in 2026.[19]
- Japan was projected to represent approximately 4.9% of global pharmaceutical quality-control and compliance revenue in 2026.[19]
- North America accounted for 38.27% of the global pharmaceutical quality-control and compliance market in 2025.[19]
- Europe’s pharmaceutical quality-control and compliance market was projected to grow at a 7.90% CAGR during the forecast period.[19]
- $7.2 billion was the global data integrity and compliance systems market size in 2024, spanning pharmaceutical, biotechnology, clinical-trial and healthcare applications worldwide.[20]
Supplier management in the data integrity pharmaceutical industry
- FDA identified significant data-integrity concerns in clinical and bioanalytical studies conducted by Synapse Labs, a contract research organization in Pune, India, in 2024.[56]
- FDA reported that Viatris’s global quality organization became aware of data-integrity issues involving component testing in January 2024.[56]
Stakeholder management in the data integrity pharmaceutical industry
- Domestic FDA drug-quality-assurance inspections increased from 432 in fiscal 2024 to 702 in fiscal 2025.[65]
- FDA issued 105 warning letters to human-drug manufacturing sites for drug-quality reasons in fiscal year 2024.[65]
- FDA conducted 766 drug-quality-assurance inspections in fiscal year 2023.[65]
- FDA issued 94 warning letters to drug-manufacturing sites for drug-quality reasons in fiscal year 2023.[56]
- FDA conducted 972 drug-quality-assurance inspections in fiscal year 2024.[65]
Key questions about the data integrity pharmaceutical industry
What size market is the data integrity pharmaceutical industry using as a proxy?
How fast is the quality-management proxy expected to grow into 2033?
Which companies lead the data integrity pharmaceutical industry?
What technology shift shows up most in 2025–2026 adoption signals?
How is market structure reflected in geography and deployment?
Which compliance evidence keeps data-integrity spend tied to enforcement outcomes?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 11). Data Integrity Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/data-integrity-pharmaceutical-industry-statistics
Samuel Norberg. "Data Integrity Pharmaceutical Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/data-integrity-pharmaceutical-industry-statistics.
Samuel Norberg. 2026. "Data Integrity Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/data-integrity-pharmaceutical-industry-statistics.
Sources & references
80 sources cited across this report
capgemini.com
cpl.thalesgroup.com
ispe.org
pmmi-fonteva.s3.us-east-1.amazonaws.com
pmlive.com
ppd.com
test.benchling.com
- techresearchinfo.com
deloitte.com
insights.indegene.com
pharmamanufacturing.com
axiobench.com
veeva.com
pistoiaalliance.org
link.springer.com
wiseguyreports.com
fortunebusinessinsights.com
- htfmarketinsights.com
- lifesciencesworkforce.org
mckinsey.com
- galifesciences.org
biospace.com
- innovatebio.org
naceweb.org
- jthelander.com
assets.kpmg.com
- biobuzz.io
massbio.org
itpro.com
- amneal.com
cultureamp.com
thbi.com
crowe.com
acrpnet.org
pro.carenity.com
fiercepharma.com
health-union.com
klick.com
- img.etb2bimg.com
sermo.com
- brand-news.it
jamanetwork.com
pmc.ncbi.nlm.nih.gov
- pure.dongguk.edu
raps.org
iqvia.com
glginsights.com
doi.org
pmmi.org
nsf.org
sgs.com
expresspharma.in
fda.gov
middlemarketcenter.org
- lifesciencesny.org
acrohealth.org
fortinet.com
kiteworks.com
- openpharma.blog
etla.fi
- insights.economistenterprise.com
- pharmafocusamerica.com
grandviewresearch.com
- gmpnews.org
ir.waters.com
agilent.com
- labsystemsindex.com
honeywell.com
3ds.com
siemens.com
mastercontrol.com
koerber-pharma.com
compliancequest.com
ema.europa.eu
database.ich.org
who.int
Social media in the data integrity pharmaceutical industry